Home / Markets / News / Sun Pharma to test two drugs for treatment of Covid-19, stock up 3.5%

Sun Pharma to test two drugs for treatment of Covid-19, stock up 3.5%

At present there are three clinical trials underway to test nafamostat in Covid19 patients around the world

Premium

Nafamostat is currently not sold in India

3 min read Last Updated : May 30 2020 | 1:37 AM IST

India’s largest drug maker Sun Pharmaceutical Industries is readying to start trials on a few drugs that have emerged as potential treatment candidates for Covid-19. This includes an anti-coagulant and anti-inflammatory drug nafamostat and another plant-based dengue drug candidate that Sun Pharma was developing along with government research institutes.

The development comes at a time when several Indian companies are lining up testing of potential drug candidates on Covid-19 patients. Mumbai-based Glenmark, too, has started trials on favipiravir, an influenza drug that has shown some promise.

On Friday, Sun Pharma said it received the nod from the Drug Controller General of India

Topics : Coronavirus Sun Pharma Vaccine drug testing Pharma stocks

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in